Zimmer Biomet Holdings Inc (ZBH) Shares Sold by HM Payson & Co.

HM Payson & Co. reduced its stake in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 7.2% in the 3rd quarter, HoldingsChannel reports. The firm owned 4,101 shares of the medical equipment provider’s stock after selling 317 shares during the quarter. HM Payson & Co.’s holdings in Zimmer Biomet were worth $539,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Calamos Advisors LLC grew its holdings in shares of Zimmer Biomet by 6.8% during the third quarter. Calamos Advisors LLC now owns 36,675 shares of the medical equipment provider’s stock valued at $4,822,000 after buying an additional 2,322 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Zimmer Biomet by 9.8% during the third quarter. JPMorgan Chase & Co. now owns 11,595,444 shares of the medical equipment provider’s stock valued at $1,524,453,000 after buying an additional 1,033,717 shares during the last quarter. Flinton Capital Management LLC grew its holdings in shares of Zimmer Biomet by 8.0% during the second quarter. Flinton Capital Management LLC now owns 12,444 shares of the medical equipment provider’s stock valued at $1,387,000 after buying an additional 918 shares during the last quarter. Schroder Investment Management Group grew its holdings in shares of Zimmer Biomet by 71.5% during the second quarter. Schroder Investment Management Group now owns 64,996 shares of the medical equipment provider’s stock valued at $7,233,000 after buying an additional 27,096 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Zimmer Biomet by 0.8% during the second quarter. Dimensional Fund Advisors LP now owns 957,471 shares of the medical equipment provider’s stock valued at $106,700,000 after buying an additional 7,733 shares during the last quarter. 87.92% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet stock opened at $117.02 on Monday. Zimmer Biomet Holdings Inc has a fifty-two week low of $104.28 and a fifty-two week high of $134.55. The stock has a market cap of $23.87 billion, a P/E ratio of 14.57, a PEG ratio of 2.37 and a beta of 1.16. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.96 and a current ratio of 1.89.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Friday, October 26th. The medical equipment provider reported $1.63 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.60 by $0.03. The firm had revenue of $1.84 billion for the quarter, compared to analysts’ expectations of $1.84 billion. Zimmer Biomet had a net margin of 22.42% and a return on equity of 12.88%. The company’s quarterly revenue was up 1.3% on a year-over-year basis. During the same period in the previous year, the company earned $1.72 earnings per share. As a group, research analysts anticipate that Zimmer Biomet Holdings Inc will post 7.64 earnings per share for the current year.

A number of brokerages have recently issued reports on ZBH. UBS Group began coverage on shares of Zimmer Biomet in a report on Tuesday, November 27th. They set a “buy” rating and a $140.00 price objective for the company. Zacks Investment Research reiterated a “hold” rating on shares of Zimmer Biomet in a report on Saturday, November 17th. Leerink Swann reduced their price objective on shares of Zimmer Biomet from $146.00 to $141.00 and set an “outperform” rating for the company in a report on Monday, October 29th. Jefferies Financial Group reduced their price objective on shares of Zimmer Biomet from $145.00 to $140.00 and set a “buy” rating for the company in a report on Monday, October 29th. Finally, Citigroup reduced their price objective on shares of Zimmer Biomet from $129.00 to $122.00 and set a “neutral” rating for the company in a report on Monday, October 29th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and thirteen have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $134.90.

In other Zimmer Biomet news, VP Chad F. Phipps sold 30,100 shares of the business’s stock in a transaction dated Friday, September 21st. The shares were sold at an average price of $132.37, for a total value of $3,984,337.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.71% of the stock is owned by insiders.

COPYRIGHT VIOLATION NOTICE: This news story was published by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.com-unik.info/2018/12/03/zimmer-biomet-holdings-inc-zbh-shares-sold-by-hm-payson-co.html.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates through four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental.

Recommended Story: How is a Moving Average Calculated?

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit